Ventas (NYSE:VTR) Shares Gap Down Following Weak Earnings

Key Points

• Ventas shares fell sharply, opening at $80.42 versus a prior close of $83.34, after the healthcare REIT reported quarterly EPS of $0.13—well below the $0.98 consensus estimate.
• Despite the GAAP EPS miss, normalized FFO came in at $0.99 per share, ahead of estimates, while revenue rose 23% year over year to $1.83 billion, helped by growth in senior housing.
• Ventas maintained its quarterly dividend at $0.52 per share, representing a 2.6% annualized yield, but sentiment was pressured by a BNP Paribas price-target cut to $93 and the stock’s break below its 50- and 200-day moving averages.

Ventas, Inc. (NYSE:VTR - Get Free Report) shares gapped down prior to trading on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $83.34, but opened at $80.42. Ventas shares last traded at $79.7170, with a volume of 544,672 shares changing hands.

The real estate investment trust reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.98 by ($0.85). The firm had revenue of $1.83 billion for the quarter, compared to analyst estimates of $1.77 billion. During the same period in the previous year, the business earned $0.88 EPS. Ventas's quarterly revenue was up 23.0% on a year-over-year basis.

Ventas Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 15th. Shareholders of record on Wednesday, September 30th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Wednesday, September 30th. Ventas's dividend payout ratio (DPR) is presently 385.19%.

Ventas News Roundup

Here are the key news stories impacting Ventas this week:

• Positive Sentiment: Ventas reported third-quarter normalized FFO of $0.99 per share, ahead of the $0.98 consensus estimate and up from $0.88 a year earlier. Revenue increased 23% year over year to $1.83 billion, exceeding the $1.77 billion forecast. Ventas Q3 Normalized FFO, Revenue Rise
• Positive Sentiment: Growth in senior housing, including strong organic performance, helped drive the quarterly beat and contributed to an increase in full-year guidance. The results suggest improving demand and operating momentum in a key Ventas business segment. Ventas Q3 2026: Senior Housing Surge Drives Guidance Raise
• Neutral Sentiment: The earnings release confirmed broad revenue and FFO growth for the quarter and first nine months of 2026. However, with a market capitalization of approximately $42.7 billion and a high reported P/E ratio, investors may require continued strong growth to support the valuation. Ventas Reports Third-Quarter and Nine-Month Results
• Negative Sentiment: BNP Paribas lowered its price target on VTR to $93 from $110. Although the revised target remains above the stock’s recent trading level, the cut signals reduced near-term upside expectations and may weigh on sentiment. BNP Paribas Adjusts Price Target on Ventas
• Negative Sentiment: VTR broke below its 200-day moving average, currently around $86.31, while also remaining below its 50-day average near $87.67. The technical breakdown can trigger additional selling and indicates weakening momentum despite the favorable earnings report. Ventas Stock Price Breaks Below 200-Day Moving Average

Analysts Set New Price Targets

A number of analysts have recently commented on the company. BNP Paribas Exane boosted their price objective on Ventas from $93.00 to $110.00 and gave the stock an "outperform" rating in a research note on Thursday, July 30th. Citigroup lifted their target price on Ventas from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Tuesday, August 4th. BMO Capital Markets boosted their price target on shares of Ventas from $105.00 to $107.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 11th. Weiss Ratings reissued a "buy (b-)" rating on shares of Ventas in a report on Monday, October 19th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Ventas from $94.00 to $104.00 and gave the company an "overweight" rating in a research report on Wednesday, September 2nd. Eighteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $98.91.

Hedge Funds Weigh In On Ventas

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Ventas during the second quarter valued at about $4,953,439,000. Dimensional Fund Advisors LP increased its position in shares of Ventas by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 7,190,594 shares of the real estate investment trust's stock worth $588,045,000 after acquiring an additional 253,019 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of Ventas in the second quarter worth approximately $501,850,000. Deutsche Bank AG acquired a new stake in shares of Ventas during the second quarter valued at approximately $451,822,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Ventas by 5.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 4,981,404 shares of the real estate investment trust's stock valued at $442,349,000 after acquiring an additional 258,859 shares during the period. Hedge funds and other institutional investors own 94.18% of the company's stock.

Ventas Price Performance

The firm has a market cap of $40.82 billion, a price-to-earnings ratio of 146.74 and a beta of 0.72. The stock's fifty day moving average price is $87.67 and its 200-day moving average price is $86.31.

About Ventas

Ventas, Inc NYSE: VTR is a real estate investment trust focused on healthcare and senior housing properties. The company owns, manages and develops a diversified portfolio of healthcare-related real estate, including senior living communities, medical office buildings, life science and innovation centers, and other properties serving healthcare providers and institutions.

Ventas generally leases its properties to healthcare operators, physicians, health systems, universities and research organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.